Biomarkers and Therapy Targets in Urologic Cancer

Dear Colleagues,

The incidence of urologic cancers has been continuously rising over the past few years, with prostate cancer having become the most prevalent cancer in men in the US today. However, treatment of urogenital malignancies is still very broad. Personalized therapy, as it is already largely practiced, e.g., in melanoma or GIST tumors, only plays a very small role in our field, mostly due to the lack of specific prognostic or predictive markers and targeted therapies. This issue of Biomedicines will therefore specifically address such new therapies and potential markers, possibly bringing GU tumor therapy to the next level.

Dr. Oliver Hahn
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.